Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INCRNASDAQ:PMNNASDAQ:SNTINASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINCRInterCure$1.49-1.0%$1.50$1.17▼$2.62$68.36M1.2226,598 shs2,889 shsPMNPromis Neurosciences$0.50+2.5%$0.54$0.47▼$2.37$15.95M-0.0879,303 shs24,315 shsSNTISenti Biosciences$2.28-18.0%$3.35$1.52▼$16.94$72.51M2.23825,452 shs3.88 million shsSTROSutro Biopharma$0.79+0.5%$0.85$0.52▼$5.17$66.73M1.71.11 million shs719,436 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINCRInterCure-1.07%-3.26%-6.01%-1.33%-35.99%PMNPromis Neurosciences+2.46%-6.54%0.00%-24.46%-68.01%SNTISenti Biosciences-17.99%-18.86%-29.63%-35.04%-7.58%STROSutro Biopharma+0.47%-3.99%-9.62%-0.28%-73.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINCRInterCure0.2194 of 5 stars0.03.00.00.00.60.00.6PMNPromis Neurosciences1.5476 of 5 stars3.52.00.00.00.00.80.6SNTISenti Biosciences2.4291 of 5 stars3.53.00.00.01.80.01.3STROSutro Biopharma4.0666 of 5 stars3.14.00.04.72.41.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINCRInterCure 0.00N/AN/AN/APMNPromis Neurosciences 3.00Buy$4.50800.00% UpsideSNTISenti Biosciences 3.00Buy$8.50272.81% UpsideSTROSutro Biopharma 2.25Hold$6.11670.26% UpsideCurrent Analyst Ratings BreakdownLatest PMN, INCR, SNTI, and STRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025STROSutro BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$2.006/12/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/6/2025SNTISenti BiosciencesLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.005/19/2025STROSutro BiopharmaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.805/12/2025PMNPromis NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.005/2/2025SNTISenti BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/29/2025STROSutro BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.004/1/2025PMNPromis NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINCRInterCure$64.55M1.05N/AN/A$2.36 per share0.63PMNPromis NeurosciencesN/AN/AN/AN/A$0.50 per shareN/ASNTISenti Biosciences$2.56M23.23N/AN/A$5.31 per share0.43STROSutro Biopharma$62.04M1.08N/AN/A$0.54 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINCRInterCure-$18.32MN/A0.00∞N/AN/AN/AN/A8/28/2025 (Estimated)PMNPromis Neurosciences$2.78M-$0.05N/AN/AN/AN/A-186.19%-98.56%8/6/2025 (Estimated)SNTISenti Biosciences-$52.79M-$10.84N/AN/AN/AN/A-177.24%-67.38%8/12/2025 (Estimated)STROSutro Biopharma-$227.46M-$2.98N/AN/AN/A-373.66%-347.60%-59.46%8/12/2025 (Estimated)Latest PMN, INCR, SNTI, and STRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025PMNPromis Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A5/8/2025Q1 2025STROSutro Biopharma-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million5/6/2025Q1 2025SNTISenti Biosciences-$0.56-$1.41-$0.85-$1.41$1.30 million$1.30 million3/31/2025Q4 2024PMNPromis Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/A3/20/2025Q4 2024SNTISenti Biosciences-$3.13-$0.67+$2.46-$0.67$2.80 million$5.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINCRInterCureN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINCRInterCure0.341.731.18PMNPromis NeurosciencesN/A3.363.36SNTISenti BiosciencesN/A4.224.22STROSutro BiopharmaN/A2.162.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINCRInterCure8.34%PMNPromis Neurosciences50.13%SNTISenti Biosciences25.73%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipINCRInterCure0.24%PMNPromis Neurosciences6.11%SNTISenti Biosciences3.12%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINCRInterCure35045.57 million45.46 millionOptionablePMNPromis Neurosciences532.69 million30.69 millionNot OptionableSNTISenti Biosciences426.08 million25.27 millionNot OptionableSTROSutro Biopharma24084.46 million81.42 millionOptionablePMN, INCR, SNTI, and STRO HeadlinesRecent News About These CompaniesSutro Biopharma, Inc. (NASDAQ:STRO) Receives $6.11 Consensus Target Price from AnalystsJune 19 at 1:47 AM | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Piper SandlerJune 17 at 2:41 AM | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Upgraded by Piper Sandler to Overweight RatingJune 16 at 8:17 AM | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by AnalystsJune 16 at 1:35 AM | marketbeat.comSutro Biopharma upgraded to Overweight from Neutral at Piper SandlerJune 16 at 1:03 AM | msn.comSutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Millennium Management LLCJune 7, 2025 | marketbeat.comSutro Biopharma, Inc. (NASDAQ:STRO) Short Interest UpdateJune 3, 2025 | marketbeat.comSutro Biopharma Appoints Greg Chow as Chief Financial OfficerJune 2, 2025 | finance.yahoo.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of "Hold" by BrokeragesMay 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Has $4.04 Million Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO)May 22, 2025 | marketbeat.com2,570,000 Shares in Sutro Biopharma, Inc. (NASDAQ:STRO) Purchased by Vestal Point Capital LPMay 21, 2025 | marketbeat.comSuvretta Capital Management LLC Grows Position in Sutro Biopharma, Inc. (NASDAQ:STRO)May 19, 2025 | marketbeat.comSutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 9, 2025 | finanznachrichten.deSutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comSutro Biopharma Reports First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | globenewswire.comSutro Biopharma to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%April 26, 2025 | aaii.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%April 1, 2025 | aaii.comWhy Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%March 18, 2025 | aaii.comSutro Biopharma downgraded to Neutral from Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comHC Wainwright & Co. Downgrades Sutro Biopharma (STRO)March 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines5 Small-Cap Stocks to Watch for Big Speculative GainsBy Thomas Hughes | May 21, 2025View 5 Small-Cap Stocks to Watch for Big Speculative GainsNew Catalysts to Drive NVIDIA’s Stock Price Even HigherBy Thomas Hughes | June 16, 2025View New Catalysts to Drive NVIDIA’s Stock Price Even HigherSalesforce’s Stock Price Presents an Opportunity to BuyBy Thomas Hughes | May 29, 2025View Salesforce’s Stock Price Presents an Opportunity to BuyAppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayBy Leo Miller | June 10, 2025View AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target AnywayCostco Stock at $1K: Dominance or Danger Zone?By Jeffrey Neal Johnson | May 23, 2025View Costco Stock at $1K: Dominance or Danger Zone?PMN, INCR, SNTI, and STRO Company DescriptionsInterCure NASDAQ:INCR$1.48 -0.02 (-1.00%) Closing price 06/18/2025 03:57 PM EasternExtended Trading$1.48 0.00 (0.00%) As of 06/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Promis Neurosciences NASDAQ:PMN$0.50 +0.01 (+2.46%) Closing price 06/18/2025 03:50 PM EasternExtended Trading$0.50 0.00 (0.00%) As of 06/18/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Senti Biosciences NASDAQ:SNTI$2.28 -0.50 (-17.99%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.20 -0.08 (-3.51%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Sutro Biopharma NASDAQ:STRO$0.79 +0.00 (+0.47%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.84 +0.04 (+5.57%) As of 06/18/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
